Next Article in Journal
Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy
Next Article in Special Issue
Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines
Previous Article in Journal
Telomerase Biogenesis and Activities from the Perspective of Its Direct Interacting Partners
Previous Article in Special Issue
Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer
Open AccessReview

Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)

1
Medical Oncology Unit–IRCCS IstitutoTumori “Giovanni Paolo II” of Bari, 70124 Bari, Italy
2
Department of Biomedical Sciences and Human Oncology-University of Bari Medical School, 70124 Bari, Italy
3
Oncology Clinic, AOU Ospedali Riuniti, Polytechnic University of Marche, 60121 Ancona, Italy
4
Department of Pathology, Hospital Cà Foncello of Treviso, 31100 Treviso, Italy
5
Medical Oncology Unit Azienda Ospedaliera San Giovanni Calibita Fatebene fratelli Roma, 00186 Roma, Italy
6
Division of Pancreatic Surgery, Vita-Salute University, San Raffaele Scientific Institute, 20132 Milan, Italy
7
Department of Radiology, G. B. Rossi University Hospital, University of Verona, 37129 Verona, Italy
8
Radiation Oncology, Campus Bio-Medico University, 00128 Rome, Italy
9
Medical Oncology Unit, Department of Oncology and Robotic Surgery, AOU Careggi, 50139 Florence, Italy
10
Section of Medical Oncology, Department of Medicine, University of Verona and University Hospital Trust, 37129 Verona, Italy
11
Department of Gastroenterology, San Carlo Hospital, 85100 Potenza, Italy
12
Division of Medical Oncology, Pisa University Hospital, 56124 Pisa, Italy
13
Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(6), 1681; https://doi.org/10.3390/cancers12061681
Received: 29 April 2020 / Revised: 21 June 2020 / Accepted: 22 June 2020 / Published: 24 June 2020
(This article belongs to the Special Issue Advances in Pancreatic Cancer Research)
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations. View Full-Text
Keywords: pancreatic ductal adenocarcinoma; guidelines; recommendations; diagnosis; treatment; follow-up pancreatic ductal adenocarcinoma; guidelines; recommendations; diagnosis; treatment; follow-up
MDPI and ACS Style

Silvestris, N.; Brunetti, O.; Bittoni, A.; Cataldo, I.; Corsi, D.; Crippa, S.; D’Onofrio, M.; Fiore, M.; Giommoni, E.; Milella, M.; Pezzilli, R.; Vasile, E.; Reni, M. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers 2020, 12, 1681.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop